Lilly reports new data on PCSK9 base editing gene therapy from Verve buyout
Eli Lilly said a base editing gene therapy from its purchase of Verve Therapeutics delivered additional positive results in a Phase 1b trial, paving the way for...
Eli Lilly said a base editing gene therapy from its purchase of Verve Therapeutics delivered additional positive results in a Phase 1b trial, paving the way for a mid-stage test by year’s ...